Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasidotin in Docetaxel-Treated HRPC
NCT00082134Phase 2Completed
- Sponsor
- Sanofi
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tasidotin in prostate cancer (PCa), sponsored by Sanofi. Primary endpoint: Prostate-Specific Antigen Response Rate. Status: completed.
02
Drugs
tasidotin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00082134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082134.